Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-07-22Clinical Trial Update: YH1 in Poorly Controlled Type 2 Diabetes [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial update for YH1 in poorly controlled Type 2 Diabetes has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-07-19Clinical Trial Update: Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"
A completed clinical trial (NCT02221284) studying alogliptin tablets in Type 2 diabetes patients on combination therapy with a hypoglycemic …
-
CLINICAL_TRIALS trial_result · 2019-07-18Clinical Trial Update: Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus [Phase 2]
A Phase 2 clinical trial evaluating the efficacy and safety of DWP16001 in patients with Type 2 Diabetes Mellitus is underway, with status c…
-
CLINICAL_TRIALS trial_result · 2019-07-17Clinical Trial Update: Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients [Phase 3]
Phase 3 trial comparing insulin lispro biphasic 25 to Humalog Mix 25 in adults with type 2 diabetes completed.
-
CLINICAL_TRIALS trial_result · 2019-07-16Clinical Trial Update: A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors [Phase 4]
Phase 4 trial evaluating long-term lorcaserin (BELVIQ) on major adverse cardiovascular events and conversion to type 2 diabetes in obese/ove…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-07-16Clinical Trial Update: Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3) [NA]
A completed clinical trial evaluating continuous glucose monitors to regulate glucose levels in adults with Type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2019-07-10Clinical Trial Update: LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. [Phase 3]
Phase 3 trial evaluating add-on liraglutide vs placebo in people taking SGLT2 inhibitors for type 2 diabetes; study completed with results p…
-
CLINICAL_TRIALS trial_result · 2019-07-10Clinical Trial Update: REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs [Phase 4]
Phase 4 trial update investigating gender response to PDE5 inhibitors in diabetic cardiomyopathy and type 2 diabetes patients; study complet…
-
CLINICAL_TRIALS trial_result · 2019-07-10Clinical Trial Update: Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus [Phase 3]
Phase 3 trial evaluating the effects of liraglutide on cognitive function in patients with type 2 diabetes mellitus has completed.
-
CLINICAL_TRIALS trial_result · 2019-07-10Clinical Trial Update: An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2
An observational study of alogliptin benzoate in adults with type 2 diabetes mellitus has been completed and results posted.
-
CLINICAL_TRIALS trial_result · 2019-07-09Clinical Trial Update: Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients [Phase 3]
Phase 3 trial comparing Insulin Rinsulin NPH to Humulin NPH in adults with type 2 diabetes mellitus; study completed.
-
CLINICAL_TRIALS trial_result · 2019-07-09Clinical Trial Update: Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? [Phase 4]
Phase 4 trial evaluating whether dapagliflozin can regress left ventricular hypertrophy in patients with type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2019-07-09Clinical Trial Update: Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) [NA]
Clinical trial update on growth hormone feedback to IGF-1 and OGTT in adults with acromegaly and type 2 diabetes mellitus; the study is comp…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain. [Phase 4]
Phase 4 clinical trial update evaluating transporters for organic cations and glycemic control in patients with neuropathic pain and type 2 …
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV
A completed clinical trial analyzing characteristics and practice patterns of type 2 diabetes patients treated with oral antidiabetic drugs …
-
FDA approval · 2019-07-03FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for TRADJENTA (linagliptin) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.
-
FDA approval · 2019-07-03FDA Approved: JENTADUETO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for JENTADUETO (linagliptin and metformin hydrochloride) from Boehringer Ingelheim Pharmaceuticals, …
-
FDA label_change · 2019-07-03FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc., updati…
-
FDA approval · 2019-07-03FDA Approved: JENTADUETO XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for JENTADUETO XR (linagliptin and metformin hydrochloride) by Boehringer Ingelheim Pharmaceutic…
-
FDA approval · 2019-07-01FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved a supplemental application from Padagis Israel Pharmaceuticals Ltd for a fixed-dose combination tablet of alogliptin benzoa…
-
FDA approval · 2019-07-01FDA Approved: JANUMET — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for JANUMET (sitagliptin and metformin hydrochloride) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2019-07-01FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for JANUMET XR (sitagliptin and metformin hydrochloride) filed by Merck Sharp & Dohme LLC.
-
FDA approval · 2019-07-01FDA Approved: ALOGLIPTIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for alogliptin, a diabetes medication, submitted by Padagis Israel Pharmaceuticals Ltd, reflecting c…
-
FDA approval · 2019-07-01FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc. The…
-
FDA approval · 2019-07-01FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for STEGLUJAN, a fixed-dose combination of ertugliflozin and sitagliptin, developed by Merck Sharp &…